Related Experiment Video
Updated: May 23, 2026

08:58
En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
Published on: February 25, 2016
Uncoupling protein-2 protects endothelial function in diet-induced obese mice
Xiao Yu Tian1, Wing Tak Wong, Aimin Xu
1Institute of Vascular Medicine, Hong Kong SAR, China.
Circulation Research
|March 31, 2012
Summary
Uncoupling protein-2 (UCP2) protects against endothelial dysfunction in obesity and diabetes by reducing reactive oxygen species (ROS) and increasing nitric oxide (NO) bioavailability, preserving vascular health.
Area of Science:
- Vascular Biology
- Metabolic Disease
- Mitochondrial Function
Background:
- Uncoupling protein-2 (UCP2) is recognized for its antioxidant role in hypertension-related endothelial dysfunction.
- UCP2 influences insulin secretion and action, but its specific role in obesity and diabetes-associated endothelial dysfunction remains under investigation.
Purpose of the Study:
- To investigate the protective role of UCP2 against endothelial dysfunction in obesity and diabetes.
- To determine if UCP2 mitigates endothelial dysfunction by inhibiting reactive oxygen species (ROS) and enhancing nitric oxide (NO) bioavailability.
Main Methods:
- Assessed endothelium-dependent relaxation (EDR) and flow-mediated vasodilatation in mouse aortae and mesenteric arteries.
- Utilized wire myography and pressure myography techniques.
- Measured ROS production using CM-H(2)DCFDA and DHE fluorescence.
- Examined UCP2 knockout (KO) and UCP2-overexpressing (AdUCP2) mouse models under high-glucose and high-fat diet (DIO) conditions.
Main Results:
- High-glucose exposure impaired EDR, an effect exacerbated in UCP2 KO mice and restored by AdUCP2.
- Endothelial dysfunction in DIO mice was more severe in UCP2 KO mice and improved by AdUCP2 treatment.
- UCP2 overexpression reduced ROS production and enhanced NO bioavailability, preserving endothelial function in obese diabetic mice.
Conclusions:
- UCP2 plays a critical role in preserving endothelial function in the context of obesity and diabetes.
- UCP2 exerts its protective effects by inhibiting ROS production and subsequently increasing NO bioavailability within the endothelium.
Related Concept Videos
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

